Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 11 for:    novavax | rsv

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03026348
Recruitment Status : Completed
First Posted : January 20, 2017
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
Novavax

Tracking Information
First Submitted Date  ICMJE January 17, 2017
First Posted Date  ICMJE January 20, 2017
Last Update Posted Date August 31, 2018
Study Start Date  ICMJE January 2017
Actual Primary Completion Date April 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 17, 2017)
  • Neutralizing antibody titers to at least one RSV/A strain [ Time Frame: Day 0, 21, 28 ]
  • Subjects with solicited local and systemic AEs occurring within the 7-day period following dosings on Day 0 and Day 21 and all adverse events, solicited and unsolicited, occurring within the 56-day period of Day 0. [ Time Frame: Day 0 - Day 6, Day 21 - Day 27; Day 0 - Day 56 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 17, 2017)
  • Serum concentrations of antibodies competitive with palivizumab (i.e., PCA) for binding to the RSV F protein. [ Time Frame: Day 0, 21, 28, 56, 119, 385 ]
  • Serum IgG antibody concentrations as ELISA units (EUs) specific for the F protein antigen. [ Time Frame: Day 0, 21, 28, 56, 119, 385 ]
  • Counts of IFN-γ spot forming units following in vitro stimulation of Day 0, Day 7, and Day 28 PBMC isolates with RSV F peptides. [ Time Frame: Day 0, 7, 28 ]
  • Counts and proportions of Day 0, Day 7, and Day 28 peripheral blood T cells positive by intracellular staining for IL-2, IFN-γ, or TNF-α production (alone or any combination thereof) following in vitro stimulation with RSV F peptides. [ Time Frame: Day 0, 7, 28 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
Official Title  ICMJE Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
Brief Summary This is a randomized, observer-blind, trial in clinically-stable older adults. Up to 300 eligible older adults 60 through 80 years of age will be enrolled at a 1:1 ratio into multiple dose/formulation treatment arms. Safety and immunogenicity data through Day 56 will be used to select a vaccine candidate to potentially evaluate in a Part 2 study. Proportions of subjects in various strata will not be pre-specified and the goal will be to achieve an approximately equal distribution of subjects with these characteristics across the treatment groups. Serology measures consistent with the study outcomes will be reported.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Respiratory Syncytial Viruses
Intervention  ICMJE
  • Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
  • Biological: RSV F Vaccine
  • Biological: Matrix-M1 Adjuvant
  • Other: Phosphate Buffer
Study Arms  ICMJE
  • Active Comparator: Treatment Group A
    Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group B
    Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group C
    Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
    Intervention: Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
  • Active Comparator: Treatment Group D
    Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group E
    Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
    Intervention: Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
  • Active Comparator: Treatment Group F
    Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group G
    Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
  • Active Comparator: Treatment Group H
    Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group J
    Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
  • Active Comparator: Treatment Group K
    Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group L
    Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
  • Placebo Comparator: Treatment Group M
    Day 0 Phosphate Buffer Day 21 Phosphate Buffer
    Intervention: Other: Phosphate Buffer
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 17, 2017)
300
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 18, 2018
Actual Primary Completion Date April 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and females 60 through 80 years of age who are ambulatory and live in the community or in an assisted-living facility that provides minimal assistance, such that the subject is primarily responsible for self-care and activities of daily living. Subjects may have one or more chronic medical diagnoses, but should be clinically stable as assessed by:

    • Absence of changes in medical therapy within one month due to treatment failure or toxicity (dose adjustments of ongoing therapies for optimal effect, or replacements within a class of drugs due to convenience or cost, will be deemed acceptable),
    • Absence of medical events qualifying as SAEs within one month of the planned vaccination on Day 0, and
    • Absence of known, current, and life-limiting diagnoses which, in the opinion of the investigator, render survival to completion of the protocol unlikely.
  2. Willing and able (on both a physical and cognitive basis) to give informed consent prior to study enrollment. To complete the consent process, all qualifying subjects will correctly answer at least 4 out of 5 questions of the informed consent form (ICF) comprehension assessment in no more than 2 attempts.
  3. Able to comply with study requirements. As the protocol procedures involve telephone contacts for safety ascertainment, eligible subjects must have a reliable access to a telephone.

Exclusion Criteria:

  1. Received any prior RSV vaccine.
  2. Participation in research involving any additional investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.
  3. History of a serious reaction to any prior vaccination or a history of Guillain-Barré syndrome (GBS) within 6 weeks of any prior influenza immunization.
  4. Receipt of inactivated influenza vaccine within 14 days prior to the Day 0 dose of test article or any other vaccine within the 4 weeks prior to the Day 0 dose of test article.
  5. Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.
  6. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
  7. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
  8. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature ≥ 38.0°C on the planned day of vaccine administration).
  9. Known disturbance of coagulation. Potential subjects receiving aspirin, clopidogrel, prasugrel, dipyridamole, dabigatran, apixaban, rivaroxaban, or warfarin under good control for cardiovascular prophylaxis or prophylaxis of thromboembolic disease or stroke in the setting of atrial fibrillation will NOT be excluded.
  10. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
  11. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic, cognitive, or psychiatric conditions deemed likely to impair the quality of study compliance or safety reporting).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 60 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03026348
Other Study ID Numbers  ICMJE RSV-E-205
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Novavax
Study Sponsor  ICMJE Novavax
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Vivek Shinde, MD Novavax
PRS Account Novavax
Verification Date August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP